



DRUGS OF CURRENT INTEREST (DOCI) LIST - April 2001

The purpose of the Drugs of Current Interest (DOCI) List is to stimulate reporting for a selected group of marketed drugs in order to identify drug safety signals. The maintenance of this list by the **Canadian Adverse Drug Reaction Monitoring Program** facilitates regular monitoring and constitutes one element of post-approval assessment activities. The following criteria are considered for inclusion of drugs on the DOCI list:

- < recently marketed drugs (<2 years), with limited post-marketing experience and potential safety concern from pre-market review;
- < marketed drugs for which there are emerging safety concerns, new serious adverse drug reactions that are unlabelled in the product monograph (e.g., safety signals observed internationally);
- < the first marketed drug of a new pharmacological or chemical class of medication.

abacavir (Ziagen)	oseltamivir (Tamiflu)
alteplase (Activase rt-PA)	pioglitazone (ACTOS)
celecoxib (Celebrex)	ritonavir (Norvir)
clopidogrel (Plavix)	rituximab (Rituxan)
delavirdine (Rescriptor)	rofecoxib (Vioxx)
efavirenz (Sustiva)	rosiglitazone (Avandia)
<i>Hypericum perforatum</i> (St. John's Wort)	saquinavir (Invirase)
indinavir (Crixivan)	trastuzumab (Herceptin)
melanoma theraccine (Melacine)	zaleplon (Starnoc)
naratriptan (Amerge)	zanamivir (Relenza)
nevirapine (Viramune)	zolmitriptan (Zomig)

Également disponible en français sous le titre *Liste des médicaments d'intérêt courant (MIC)*.

ISBN 0-662-29734-2

Cat. No. H49-126/2001-2E-IN

©Minister of Public Works and Government Services Canada, 2001